Drugs / Ganaplacide
Ganaplacide
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05330273 | Apr → Nov 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05236530 | Mar → Oct 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05084651 | Nov 2021 → May 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04072302 | Sep 2014 → Nov 2017 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07235033 | Jan 2024 → Mar 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04546633 | Feb 2021 → Aug 2024 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03167242 | Aug 2017 → Jun 2021 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01753323 | Mar 2013 → Aug 2014 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05842954 | Mar 2024 → Jun 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-23 | Novartis Pharmaceuticals | Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria novartis.com ↗ |
| 2021-09-29 | Novartis Pharmaceuticals | Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria novartis.com ↗ |
| 2017-08-21 | Novartis Pharmaceuticals | Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ganaplacide | “Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group,...” PMID 37327809 ↗ Jun 20235“KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF)” NCT05842954 ↗ “ganaplacide + lumefantrine solid dispersion formulation” NCT07235033 ↗ |
| Known as | Ganaplacida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2058833 ↗ |
| Known as | GNF 156 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2058833 ↗ |
| Known as | KAF156 | “KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF)” NCT05842954 ↗ |
| Modality | Small molecule | “KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines)” PMID 27653565 ↗ Sep 2016 |
| Route | Oral | “supplied as tablets for oral use” NCT01753323 ↗ |